EUClinicalTrials.govClinical trialRecruiting
SpaceOAR Post-Market Registry Study
Official record
- Identifier
NCT07300631- Recruiting locations
countries
FranceUnited Kingdom- Interventions studied
- SpaceOAR / SpaceOAR Vue hydrogel system
- Lead sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
- Target enrolment
- 320 participants
- Study type
- OBSERVATIONAL
- Phase
- Not provided in the official record
- Status
- Recruiting
- First posted
- Dec 24, 2025
- Last updated on the registry
- Jul 30, 2026
- Age
- 18 Years
- Sex
- MALE
- Study contact
- No public contact is listed on the official record.
- Eligibility criteria
Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.
Inclusion Criteria: * All patients with a clinical diagnosis of prostate cancer planned to undergo treatment with curative intent at selected sites in the UK \& France subject to a SpaceOAR being used as usual care. * Aged 18 years old or above. * Patients who agrees to participate and has been deemed by their medical team to have capacity to provide; * verbal, informed consent over telephone as documented on the study informed consent form by the Researchers (UK only) * written, informed consent by signature of the study informed consent form (France only) * Patient covered by social security scheme (France only) Exclusion Criteria: \- Patients lacking the capacity to provide; * informed consent as documented on the study informed consent form by the - Researchers (UK only) * written, informed consent by signature of the study informed consent form (France only)
- Indexed under
- Prostate Cancer
This site does not provide medical advice
TrialBeacon only aggregates links to publicly available official information. It does not recommend, rank or evaluate any treatment, trial or medicine, and nothing here implies suitability for any individual. Please discuss anything you find with your treating doctor, and always rely on the original official page — records change over time. Full disclaimer.